JP2015521592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521592A5 JP2015521592A5 JP2015516648A JP2015516648A JP2015521592A5 JP 2015521592 A5 JP2015521592 A5 JP 2015521592A5 JP 2015516648 A JP2015516648 A JP 2015516648A JP 2015516648 A JP2015516648 A JP 2015516648A JP 2015521592 A5 JP2015521592 A5 JP 2015521592A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- isolated polypeptide
- seq
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 230000002163 immunogen Effects 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 239000010410 layer Substances 0.000 claims description 12
- 239000013638 trimer Substances 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 239000011229 interlayer Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- -1 and V59 and S109 Chemical compound 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661050P | 2012-06-18 | 2012-06-18 | |
| US61/661,050 | 2012-06-18 | ||
| PCT/EP2013/062553 WO2013189901A1 (en) | 2012-06-18 | 2013-06-17 | Stabilized gp120 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015521592A JP2015521592A (ja) | 2015-07-30 |
| JP2015521592A5 true JP2015521592A5 (cg-RX-API-DMAC7.html) | 2016-08-04 |
Family
ID=48628698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516648A Pending JP2015521592A (ja) | 2012-06-18 | 2013-06-17 | 安定化されたｇｐ１２０ |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3189067B1 (en) | 2014-09-04 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| EP3197486A1 (en) * | 2014-09-23 | 2017-08-02 | Merial Inc. | Fmdv recombinant vaccines and uses thereof |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US10808011B2 (en) | 2016-03-09 | 2020-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant HIV-1 envelope proteins and their use |
| CA3200275A1 (en) * | 2016-10-21 | 2018-04-26 | Nantcell, Inc. | Multimeric il-15-based molecules |
| EP3697440A1 (en) | 2017-10-16 | 2020-08-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| CN109851664A (zh) * | 2017-11-30 | 2019-06-07 | 清华大学 | 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用 |
| US11311603B2 (en) | 2018-06-19 | 2022-04-26 | Nantcell, Inc. | HIV treatment compositions and methods |
| WO2021249013A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Vaccine compositions, methods, and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786488B1 (fr) * | 1998-11-27 | 2003-04-25 | Orstom | Mutants de la gp120 et leurs applications biologiques |
| EP1198468A4 (en) * | 1999-06-25 | 2003-07-30 | Progenics Pharm Inc | STABILIZED VIRAL ENVELOPE PROTEINS AND THEIR USE |
| EP2192918A1 (en) * | 2007-08-24 | 2010-06-09 | Novartis Ag | Hiv env proteins with modifications in the v3 loop |
| AU2010298025B2 (en) * | 2009-09-25 | 2016-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
-
2013
- 2013-06-17 KR KR20157000850A patent/KR20150023735A/ko not_active Withdrawn
- 2013-06-17 IN IN2740KON2014 patent/IN2014KN02740A/en unknown
- 2013-06-17 WO PCT/EP2013/062553 patent/WO2013189901A1/en not_active Ceased
- 2013-06-17 RU RU2015101081A patent/RU2015101081A/ru not_active Application Discontinuation
- 2013-06-17 SG SG11201407995RA patent/SG11201407995RA/en unknown
- 2013-06-17 CA CA2876762A patent/CA2876762A1/en not_active Abandoned
- 2013-06-17 MX MX2014014682A patent/MX2014014682A/es unknown
- 2013-06-17 JP JP2015516648A patent/JP2015521592A/ja active Pending
- 2013-06-17 US US14/408,466 patent/US20150183835A1/en not_active Abandoned
- 2013-06-17 AU AU2013279456A patent/AU2013279456A1/en not_active Abandoned
- 2013-06-17 CN CN201380032027.2A patent/CN104619338A/zh active Pending
- 2013-06-17 EP EP13729364.3A patent/EP2861249A1/en not_active Withdrawn
-
2014
- 2014-11-25 IL IL235898A patent/IL235898A0/en unknown
- 2014-12-02 ZA ZA2014/08840A patent/ZA201408840B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521592A5 (cg-RX-API-DMAC7.html) | ||
| RU2015101081A (ru) | Стабилизированный gp120 | |
| US20250171501A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| WO2009002418A3 (en) | T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof | |
| JP2010522540A5 (cg-RX-API-DMAC7.html) | ||
| WO2007106476A3 (en) | Compositions and methods for enhancing the immunogenicity of antigens | |
| JP2014500724A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500827A5 (cg-RX-API-DMAC7.html) | ||
| JP2013529078A5 (cg-RX-API-DMAC7.html) | ||
| SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
| JP2012530504A5 (cg-RX-API-DMAC7.html) | ||
| JP2018512856A5 (cg-RX-API-DMAC7.html) | ||
| FI3294333T4 (fi) | Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit | |
| JP2009520758A5 (cg-RX-API-DMAC7.html) | ||
| IL255769B2 (en) | shared neoantigens | |
| JP2012500001A5 (cg-RX-API-DMAC7.html) | ||
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| WO2006036550A3 (en) | Listeria-based and llo-based vaccines | |
| IL274130B2 (en) | Novel scaffolded hiv-1 vaccine immunogens | |
| US20240358812A1 (en) | Human metapneumovirus combination vaccine | |
| MX2016008989A (es) | Fragmentos mutantes de ospa y metodos y usos relacionados con estos. | |
| JP2016504993A5 (cg-RX-API-DMAC7.html) | ||
| UA107180C2 (uk) | Туберкульозний білок rv1753c, композиція, що його містить, та застосування |